Skip to main content

Nasdaq IPOs

Radio network provider Ondas sets terms for $30 million IPO

5 years 10 months ago
Ondas Holdings, which provides a software-defined radio system to create private broadband networks, announced terms for its IPO on Monday. The Sunnyvale, CA-based company plans to raise $30 million by offering 2.9 million shares at $10.40, the last close of its shares on the OT
Renaissance Capital

Oncology biotech Kinnate Biopharma sets terms for $170 million IPO

5 years 10 months ago
Kinnate Biopharma, an early stage biotech developing small molecule kinase inhibitors for difficult-to-treat cancers, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $170 million by offering 10 million shares at a price range of $16 to $18.
Renaissance Capital

Enterprise AI software maker C3.ai sets terms for $504 million IPO

5 years 10 months ago
C3.ai, which provides a SaaS platform for deploying enterprise AI applications, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $504 million by offering 15.5 million shares at a price range of $31 to $34. Insider BlackRock and new investo
Renaissance Capital

Unlocking the human proteome: Seer sets terms for $150 million IPO

5 years 10 months ago
Seer, which is developing next-generation proteome analysis tests for biomedical research, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18. Fidelity, SoftBank, T.
Renaissance Capital

AdTech platform PubMatic sets terms for $100 million IPO

5 years 10 months ago
PubMatic, which provides a cloud infrastructure platform that enables advertising transactions, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $100 million by offering 5.9 million shares (45% primary) at a price range of $16 to $18. At t
Renaissance Capital

Biotech IPOs close to beating Covid-19

5 years 10 months ago
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in December 2018. However, B
Renaissance Capital
Checked
5 minutes 5 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed